Pulmonary Exacerbation
Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data.
Patients with severe eosinophilic asthma, prior biologic use benefit from benralizumab
Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results published in European Respiratory Journal.
Benralizumab for eosinophilic asthma/COPD exacerbations ‘could be a game-changer’
Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results published in The Lancet Respiratory Medicine.
Dipeptidylpeptidase-1 inhibitor lowers exacerbation incidence in bronchiectasis
Among Chinese adults with bronchiectasis and exacerbations in the past year, 24-week dipeptidylpeptidase-1 inhibitor HSK31858 lowered exacerbation incidence, according to a poster at the European Respiratory Society International Congress.
Bronchiectasis plus chronic respiratory infection raises exacerbation risk
Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and hospitalization within 2 years of diagnosis, according to results published in BMC Pulmonary Medicine.
Tozorakimab may benefit adults with COPD plus bronchitis
Among adults with COPD and bronchitis, receiving 600 mg of tozorakimab every 4 weeks may lead to FEV1 improvement, according to a poster presented at the European Respiratory Society International Congress.
Brensocatib slows lung function decline, improves quality of life in bronchiectasis
Patients with non-cystic fibrosis bronchiectasis experienced less FEV1 and FVC decline and had improved quality of life with 52-week once-daily brensocatib vs. placebo, according to findings presented at the World Bronchiectasis Conference.
FDA approves Ohtuvayre as maintenance treatment for COPD
The FDA has approved the phosphodiesterase enzyme 3 and 4 inhibitor ensifentrine, now named Ohtuvayre, for treating adults with COPD, according to a manufacturer-issued press release.
Indigenous ethnicity raises odds for antibiotic response in pediatric bronchiectasis
The odds for symptom resolution after a 14-day antibiotic treatment for nonsevere exacerbation of bronchiectasis increased among Indigenous children and children with low cough scores, according to results published in CHEST.
ICER council votes on effectiveness of add-on ensifentrine for COPD
During a Midwest Comparative Effectiveness Public Advisory Council public meeting, 11 of 15 members believed current evidence was adequate in showing the net health benefit of ensifentrine plus maintenance therapy.